Intuitive Surgical insider 10b5-1 sale after option exercise
Rhea-AI Filing Summary
Intuitive Surgical (ISRG): Director transaction disclosed. Director Craig H. Barratt exercised a non-qualified stock option for 2,193 shares at an exercise price of $71.3233 on 10/24/2025 and sold 2,193 shares at $548.01 the same day under a Rule 10b5-1 trading plan.
Following the transactions, direct common stock holdings were 0 shares, and indirect holdings were 27,198 shares held by a trust. The filing also reports 750 derivative securities (options) remaining beneficially owned directly. The trading plan complies with Rule 10b5-1 and expires on April 29, 2026. The option was granted under the Non-Employee Directors' Stock Option Plan with vesting as noted in the plan terms.
Positive
- None.
Negative
- None.
Insights
Routine 10b5-1 option exercise and same-day sale; neutral.
The disclosure shows a standard option exercise (code M) of 2,193 shares at an exercise price of $71.3233, followed by a same-day sale (code S) of 2,193 shares at $548.01. These were executed under a Rule 10b5-1 plan, indicating pre-set instructions.
Post-transaction, direct common stock was 0 shares, with 27,198 shares held indirectly by a trust and 750 options remaining directly owned. Such activity is administrative and does not by itself signal a change in business fundamentals.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 2,193 | $0.00 | -- |
| Exercise | Common Stock | 2,193 | $71.3233 | $156K |
| Sale | Common Stock | 2,193 | $548.01 | $1.20M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 29, 2026. Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.